A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
← catalyst calendarNCT07363694 · readout in 1,527 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 2/3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
1,156estimated
Sites
103
Countries
Argentina, Canada, China +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-11 | actual | When the study began enrolling |
| Primary completion | 2030-10-24 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-01-16 | estimated | The whole study's end, after follow-up |
| First posted | 2026-01-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Moderate to Severe Chronic Obstructive Pulmonary Disease
Interventions
- Drug: PF-07275315 dose 1
- Drug: PF-07275315-dose 2
- Drug: Placebo
- Drug: PF-07275315-dose 3
Primary outcomes
what the primary-completion date above is the date OFPhase 2 part: Change from baseline in pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 24
measured Baseline to Week 24
Phase 3 part: Annualized rate of moderate or severe ECOPD
measured Baseline to Week 52
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed